Format

Send to

Choose Destination
Nat Rev Cancer. 2009 Mar;9(3):167-81. doi: 10.1038/nrc2583.

Beyond chemotherapy: targeted therapies in ovarian cancer.

Author information

1
The Royal Marsden NHS Foundation Trust, Downs Road, Sutton, Surrey, SM2 5PT, UK. stan.kaye@rmh.nhs.uk

Abstract

Ovarian cancer is the leading cause of death from gynaecological malignancies in the Western world. Despite the evolution of surgical techniques and meticulously designed chemotherapy regimens, relapse remains almost inevitable in patients with advanced disease. In an age when great advances have been made in understanding the genetics and molecular biology of this heterogeneous disease, it is likely that the introduction of novel targeted therapies will have a major impact on the management of ovarian cancer. Importantly, such strategies might allow selection of treatments based on the molecular characteristics of tumours and bring us closer to an era of personalized medicine.

TRIAL REGISTRATION:

ClinicalTrials.gov NCT00429793 NCT00523432 NCT00610714 NCT00628251 NCT00753545.

PMID:
19238149
DOI:
10.1038/nrc2583
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center